CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 147,777 enrolled
Drug / intervention
Vortioxetine Tablet +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05932407
NCT05932407N/ACompleted
CompareCT.gov

Post-marketing Database Survey: A Cohort Study of Comparison the Risk of Haemorrhage (Serious Intracranial Haemorrhage Such as Cerebral Haemorrhage and Subarachnoid Haemorrhage) Between Vortioxetine Tablets and SSRIs In Patients With Depression Using JMDC Claims Database

Takeda·observational·Posted Jul 6, 2023·Updated Mar 3, 2025

In Brief

An observational study evaluating Vortioxetine Tablet and SSRI for Major Depressive Disorder. Completed, enrolled 147,777 participants across 1 site.

Detailed Summary

This study is a retrospective database study in Japan to evaluate the relative risk of serious intracranial hemorrhage requiring hospitalization between Vortioxetine tablet treatment and selective serotonin reuptake inhibitor (SSRI) treatment for patients with depression. This survey will conduct in use of medical database called JMDC claims database.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedJul 6, 2023
Enrollment StartJun 1, 2024
Primary CompletionSep 9, 2024
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.0 years ago

Interventions

Vortioxetine Tabletdrug

Vortioxetine Tablet

SSRIdrug

SSRI: Selective Serotonin Reuptake Inhibitor